Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2CNS 1

Conditions

Pheochromocytoma 2Neuroblastoma 1Endocrine System Diseases 1

Interventions

Magnetic Resonance Spectroscopy 15lutetium Lu 177 dotatate 14Specimen Handling 14cabozantinib 10Nivolumab 10pembrolizumab 8Everolimus 8gallium Ga 68 dotatate 7Ipilimumab 6Cisplatin 6Carboplatin 6Etoposide 5trametinib 4olaparib 4lenvatinib 4X-Rays 4Lutetium-177 4Cyclophosphamide 4CTLA-4 Antigen 4fluorodopa F 18 3fludarabine 3dabrafenib 3cemiplimab 3Temozolomide 3Surveys and Questionnaires 3Phantoms, Imaging 3Immunoglobulin G 3Fluorodeoxyglucose F18 3Disulfides 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
6-fluorodopamine × Endocrine × 90 days × Clear all
NCT00004847 2026-06-03

Diagnosis of Pheochromocytoma

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
3,000 enrolled
Endocrine

Endocrine System Diseases, Pheochromocytoma

NCT03541720 2026-04-29

18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma

St. Jude Children's Research Hospital

Phase EARLY_PHASE1 Active not recruiting
13 enrolled
CNSEndocrine

Neuroblastoma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡